<DOC>
	<DOCNO>NCT00937417</DOCNO>
	<brief_summary>RATIONALE : Vandetanib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving vandetanib together docetaxel may kill tumor cell . PURPOSE : This phase I trial study side effect best dose vandetanib give together docetaxel treat patient advance solid tumor .</brief_summary>
	<brief_title>S0716 Vandetanib Docetaxel Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To investigate differential biological effect tumor tissue pharmacodynamic endpoint ( percent inhibition pERK , pKDR , pEGFR ) correlation pharmacokinetics vandetanib combination docetaxel patient advance solid tumor . - To correlate pharmacodynamic endpoint pharmacokinetics combination regimen patient . - To recommend optimal biological dose combination regimen test . Secondary - To correlate pharmacokinetics safety profile two dose level vandetanib give combination docetaxel . - To investigate scientific correlate , include serum proteomics microvessel density ( CD31 ) cell death ( TUNEL ) use tumor tissue biopsy sample take baseline treatment . - To determine objective response patient measurable disease baseline . OUTLINE : This multicenter study . Patients receive docetaxel IV 1 hour day 1 oral vandetanib daily day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After 6 week treatment , patient experience clinical benefit poor tolerance docetaxel may continue treatment vandetanib alone . Plasma sample collect periodically pharmacokinetic analysis , measurement vandetanib trough level , serum biomarker analysis , serum proteomics . Tumor tissue sample collect baseline day 36-38 pharmacodynamic analysis . After completion study treatment , patient follow 28 day .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced solid tumor , include , limited following : Nonsmall cell lung cancer Metastatic breast cancer Hormonerefractory prostate cancer Locally recurrent metastatic head neck cancer ( include thyroid origin ) Disease standard therapy exist Tumor amenable biopsy Measurable nonmeasurable disease Brain metastases allow provided patient undergone brain irradiation ( whole brain gamma knife ) AND metastases clinically radiologically stable ≥ 6 week completion irradiation Patients require corticosteroid anticonvulsant brain metastasis must stable decrease dose corticosteroid seizure free ≥ 28 day study enrollment PATIENT CHARACTERISTICS : Zubrod performance status 01 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 SGOT SGPT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN PT/INR ≤ 1.1 time normal Serum creatinine ≤ 1.8 time ULN OR measure estimate creatinine clearance &gt; 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study treatment Willing undergo two tumor biopsy blood tissue sample submission correlative laboratory study No clinically significant cardiovascular event , include follow : Myocardial infarction cerebrovascular accident within past 3 month Unstable angina pectoris NYHA class IIIV heart disease within past 3 month Symptomatic congestive heart failure Serious cardiac arrhythmia No history cardiac disease , investigator 's opinion , increase risk ventricular arrhythmia No history arrhythmia symptomatic require treatment ( CTCAE grade 3 ) , include follow : Multifocal premature ventricular contraction ( PVCs ) Bigeminy trigeminy Ventricular tachycardia Uncontrolled atrial fibrillation Medically control atrial fibrillation allow No asymptomatic sustain ventricular tachycardia No history evidence follow ECG : History QTc prolongation result medication require discontinuation medication Congenital long QT syndrome First degree relative unexplained sudden death 40 year age Presence leave bundle branch block QTc Bazett 's correction unmeasurable ≥ 480 msec screen ECG No uncontrolled hypertension , define consistent systolic BP &gt; 160 mm Hg consistent diastolic BP &gt; 100 mm Hg despite medical management No intractable nausea vomit No concurrent active diarrhea may affect ability absorb tolerate vandetanib No gastrointestinal ( GI ) tract disease result malabsorption syndrome requirement IV alimentation No uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease ulcerative colitis ) No history allergic reaction attribute docetaxel compound similar chemical biological composition vandetanib , include quinazoline compound ( e.g. , gefitinib erlotinib ) No history deep venous thrombosis pulmonary embolism require therapeutic anticoagulation No known HIV positivity No concurrent uncontrolled illness , include , limited following : Ongoing serious active infection Psychiatric illness social situation would limit compliance study requirement Prior concurrent malignancy histology within past 5 year allow PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy ( i.e. , ≤ grade 2 alopecia ≤ grade 1 toxicity adverse event ) Prior docetaxel monotherapy combination chemotherapeutic agent allow provided potential clinical benefit present , investigator 's opinion , combination docetaxel vandetanib No prior vandetanib No prior surgical procedure affect absorption More 14 day since prior drug short halflife ( e.g. , sorafenib sunitinib ) ( approval study coordinator require ) More 28 day since prior major surgery , chemotherapy , radiotherapy More 28 day since prior investigational agent More 2 week since prior concurrent medication associate risk cause Torsades de Pointes No concurrent therapeutic anticoagulation ( coumadin , warfarin , lowmolecular weight heparin ) Lowdose anticoagulation indwell catheter maintenance allow No concurrent medication may cause QTc prolongation No concurrent chemotherapy , hormonal therapy , radiotherapy , immunotherapy , type therapy treatment cancer , except follow : Luteinizing hormonereleasing hormone agonist Bisphosphonates</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>anaplastic thyroid cancer</keyword>
	<keyword>stage IV follicular thyroid cancer</keyword>
	<keyword>insular thyroid cancer</keyword>
	<keyword>stage IV papillary thyroid cancer</keyword>
	<keyword>recurrent thyroid cancer</keyword>
	<keyword>thyroid gland medullary carcinoma</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>hormone-resistant prostate cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>